WJ Boyle - US Patent 7,923,008, 2011 - Google Patents IIIIIIH US007923008B2 (12) United States Patent Boyle (io) Patent No.: (45) Date of Patent: US 7,923,008 B2 *Apr. 12, 2011 (54) METHODS FOR DECREASING OSTEOCLAST FORMATION OR BONE RESORPTION USING AN ANTIBODY TO OSTEOPROTEGERIN BINDING ... Related articles - All 2 versions
G Karsenty - Developmental Cell, 2011 - Elsevier A paper published in Developmental Cell that I have continuously enjoyed over the years is “Induction and Activation of the Transcription Factor NFATc1 Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts” by Takayanagi et al. I like this paper for many reasons. The ... All 2 versions
A Karadimitris, N Horwood… - US Patent …, 2011 - freepatentsonline.com Agents, which are both ceramide glucosyltransferase inhibitors and glucosidase inhibitors, may inhibit osteoclastogenesis and/or reduce osteoclast activation and, therefore, may be useful for osteolytic activity and bone loss in subjects with conditions, such as multiple myeloma. Cached
[HTML] from pnas.orgJY Li, H Tawfeek, B Bedi, X Yang… - Proceedings of the …, 2011 - National Acad Sciences The bone loss induced by ovariectomy (ovx) has been linked to increased production of osteoclastogenic cytokines by bone marrow cells, including T cells and stromal cells (SCs). It is presently unknown whether regulatory interactions between these lineages contribute to the effects of ovx in ... Cited by 1 - Related articles - All 4 versions
S Schmidt, I Nakchbandi, R Ruppert… - The Journal of Cell …, 2011 - jcb.rupress.org The blood cell–specific kindlin-3 protein is required to activate leukocyte and platelet integrins. In line with this function, mutations in the KINDLIN-3 gene in man cause immunodeficiency and severe bleeding. Some patients also suffer from osteopetrosis, but the underlying ... Cited by 2 - Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
